← Human Trials & Peer-Reviewed Studies
Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol.
Plain-language guide to PMID 19631774 (2009): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).
Key Facts
- PMID
- 19631774
- Journal
- Bone
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Glendenning P et al. (10 authors)
- DOI
- 10.1016/j.bone.2009.07.015
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
The objective of this study was to determine if ergocalciferol and cholecalciferol are equipotent therapies in vitamin D-insufficient hip fracture patients.
Why It Was Studied
All participants were also given a placebo matching the alternative treatment to maintain blinding of treatment allocation.
The primary endpoint was total serum 25OHD measured by HPLC.
Who Took Part
By PubMed's age tags, the people studied were people over 80.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
What Was Measured
The primary endpoint was total serum 25OHD measured by HPLC.
Secondary endpoints included 25OHD measured by radioimmunoassay (RIA), intact parathyroid hormone (iPTH), and bioactive (1-84) whole PTH (wPTH).
Topics PubMed links to this paper include Bone Density Conservation Agents, Calcium, Cholecalciferol, Dietary Supplements, Ergocalciferols, Hip Fractures and Parathyroid Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).
The publication is from 2009 (Bone), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compounds
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.